

CLAIMS:

1. An adenovirus particulate comprising a plurality of adenovirus particles complexed to an insoluble micro-platform material.

5

2. The adenovirus particulate of claim 1 further comprising a cell binding ligand complexed to the micro-platform material.

3. The adenovirus particulate of claim 2 wherein the cell binding ligand binds to a receptor on a dendritic cell.

10

4. The adenovirus particulate of claim 3 wherein the cell binding ligand is selected from the group consisting of GM-CSF, mannose, and mannose-6-phosphate.

15

5. The adenovirus particulate of claim 1 wherein the micro-platform material is a polymeric fiber or microbead.

6. The adenovirus particulate of claim 5 wherein the adenovirus particulate further comprises a gene encoding an antigenic polypeptide.

20

7. A method of forming a particulate composed of adenovirus particles comprising mixing adenovirus particles with an insoluble micro-platform material so that the adenovirus particles become complexed to the micro-platform material.

25

8. The method of claim 7 where the micro-platform material is a polymeric fiber or microbead.

9. The method of claim 7 wherein the adenovirus particles are complexed to the micro-platform material by a crosslinking agent.

30

10. The method of claim 8 wherein the adenovirus particles are complexed to the micro-platform material by a crosslinking agent.

11. The method of claim 9 where the cross-linking substance is a bivalent antibody.

12. The method of claim 10 where the cross-linking substance is a bivalent antibody

13. A method of forming a particulate of adenovirus particles where the adenovirus particle further comprises a gene encoding an antigenic polypeptide.

14. The method of claim 7 wherein the particulate of adenovirus particles further comprises a ligand that binds to a receptor on a dendritic cell.

15. The method of claim 14 wherein the ligand is GM-CSF, mannose, or mannose-6-phosphate.

16. The method of claim 13 wherein the particulate of adenovirus particles further comprises a ligand that binds to a receptor on a dendritic cell.

17. The method of claim 16 wherein the ligand is GM-CSF, mannose, or mannose-6-phosphate.

18. A method of transfecting a dendritic cell comprising contacting a dendritic cell with an adenovirus particulate of claim 1, thereby transfecting the cell.

19. A method of vaccinating a subject against a disease comprising administering to the subject an adenovirus particulate of claim 6, thereby vaccinating the subject against a disease.

20. A method of claim 19 where the adenovirus particulate vaccine is administered together with an adjuvant.